Acadian Asset Management LLC Increases Stake in United Therapeutics Co. (NASDAQ:UTHR)

Acadian Asset Management LLC lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,196,360 shares of the biotechnology company’s stock after acquiring an additional 51,346 shares during the quarter. Acadian Asset Management LLC owned about 2.75% of United Therapeutics worth $152,992,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in shares of United Therapeutics by 2.3% in the 2nd quarter. BlackRock Inc. now owns 5,028,058 shares of the biotechnology company’s stock valued at $568,925,000 after purchasing an additional 115,073 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of United Therapeutics by 1.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,556,200 shares of the biotechnology company’s stock valued at $176,084,000 after purchasing an additional 22,322 shares during the last quarter. First Trust Advisors LP lifted its stake in shares of United Therapeutics by 53.8% in the 3rd quarter. First Trust Advisors LP now owns 1,053,569 shares of the biotechnology company’s stock valued at $134,730,000 after purchasing an additional 368,613 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of United Therapeutics by 3.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 990,685 shares of the biotechnology company’s stock valued at $112,093,000 after purchasing an additional 32,611 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC lifted its stake in shares of United Therapeutics by 3.1% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 559,107 shares of the biotechnology company’s stock valued at $63,263,000 after purchasing an additional 16,638 shares during the last quarter. Institutional investors and hedge funds own 93.69% of the company’s stock.

Several brokerages recently commented on UTHR. Wedbush set a $253.00 target price on shares of United Therapeutics and gave the stock a “buy” rating in a report on Thursday, September 27th. HC Wainwright set a $95.00 target price on shares of United Therapeutics and gave the stock a “hold” rating in a report on Monday, August 13th. BidaskClub upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 18th. Cowen set a $106.00 target price on shares of United Therapeutics and gave the stock a “hold” rating in a report on Wednesday, October 31st. Finally, Credit Suisse Group lifted their target price on shares of United Therapeutics from $103.00 to $105.00 and gave the stock a “sell” rating in a report on Monday. Two analysts have rated the stock with a sell rating, five have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $134.00.

In other news, Director Christopher Causey sold 810 shares of United Therapeutics stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $118.00, for a total transaction of $95,580.00. Following the sale, the director now directly owns 3,925 shares in the company, valued at approximately $463,150. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.20% of the stock is currently owned by insiders.

Shares of United Therapeutics stock traded up $1.00 during trading on Thursday, hitting $114.22. 334,580 shares of the company’s stock traded hands, compared to its average volume of 433,908. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.05 and a current ratio of 4.32. United Therapeutics Co. has a twelve month low of $100.57 and a twelve month high of $152.55. The firm has a market cap of $4.93 billion, a P/E ratio of 10.49, a price-to-earnings-growth ratio of 26.43 and a beta of 1.23.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share for the quarter, missing the consensus estimate of $3.23 by ($0.81). United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The business had revenue of $412.70 million for the quarter, compared to analyst estimates of $378.22 million. During the same quarter last year, the firm posted $4.69 earnings per share. United Therapeutics’s revenue was down 7.4% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Co. will post 14.28 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Acadian Asset Management LLC Increases Stake in United Therapeutics Co. (NASDAQ:UTHR)” was posted by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://theenterpriseleader.com/2018/11/22/acadian-asset-management-llc-increases-holdings-in-united-therapeutics-co-uthr.html.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also: How mutual funds make money

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply